Therapeutic antibodies for treating liver fibrosis
用于治疗肝纤维化的治疗性抗体
基本信息
- 批准号:10011650
- 负责人:
- 金额:$ 34.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAffinityAgonistAlcohol abuseAnimal ModelAntibodiesApoptosisArchitectureBenchmarkingBiological AssayBiological MarkersBloodBlood - brain barrier anatomyBlood PressureBlood flowCNR1 geneCNR2 geneCannabinoidsCause of DeathCell LineCell divisionCellsCellular AssayCessation of lifeChemistryChronic DiseaseCicatrixCirrhosisClinicalClinical TrialsCognitiveCollagenDataDevelopmentDiseaseDisease ProgressionEffectivenessEngineeringEvaluationFatty acid glycerol estersFibrosisFutureG-Protein-Coupled ReceptorsGene ExpressionGovernmentHandHealthHepaticHepatic Stellate CellHepatocyteHistopathologyHumanImmuneIn VitroInflammationInflammatoryKupffer CellsLeadLeftLife Style ModificationLiverLiver CirrhosisLiver FailureLiver FibrosisLiver diseasesLungLung diseasesMeasuresMessenger RNAModelingMonitorMusPathologicPatientsPeripheralPersonsPharmaceutical PreparationsPharmacologyPhaseRaceRattusResearchRodent ModelRunawaySafetySamplingSclerodermaSiteTechnologyTestingTextTherapeuticTherapeutic antibodiesThioacetamideTissuesabalonebaseblood-brain barrier crossingcannabinoid receptorcell typechronic liver diseasecommon treatmentcross reactivitycytokinedesignidiopathic pulmonary fibrosisin vivoin vivo Modelinnovationliver functionliver injurymacrophagenonalcoholic steatohepatitisoxidationreceptorresponseside effectskin disordersmall moleculesuccess
项目摘要
Abstract
Cirrhosis of the liver is among the top ten leading causes of death in the US, with more than 35,000 deaths
each year. A major underlying cause of cirrhosis is liver injury associated with liver fibrosis; the pathological
indication of cirrhosis is the development of scar tissue that replaces normal parenchyma. The scar tissue
blocks the flow of blood through the liver, raising blood pressure and disturbing normal function.
Current drugs that treat fibrosis are not always effective. Patients are often left with “lifestyle modifications” that
are difficult to sustain, and, at best, put patients in a race against disease progression. Small molecule agonists
of the cannabinoid receptor CB2 have reduced liver fibrosis in several established animal models. CB2
agonists achieve this by inhibiting hepatic immune cells and hepatic stellate cells. CB2 agonism is a
promising mode of action for treating liver fibrosis. However, small molecule CB2 agonists have
drawbacks that undercut their effectiveness and safety, including cross-reactivity with CB1, crossing the blood-
brain barrier and cross-activating CB1, causing the adverse cognitive effects of cannabinoids and rapid
elimination from the body. A highly specific CB2 agonist antibody that is long-lived and restricted to
peripheral tissues would be an ideal drug to test the CB2 agonism mode of action.
Abalone Bio proposes 3 aims to test the feasibility of using CB2 agonist antibody drugs to treat liver fibrosis.
(1) Engineer, produce, characterize CB2 agonist antibodies. VHH-Fc versions of identified hits will be made and
characterized using multiple non-liver in vitro cell-based assays. (2) Assess effects of CB2 agonist antibodies
on liver cells. In this aim, the antibodies from Aim 1 will be used to characterize anti-fibrotic effects in primary
liver cells and stable liver cell lines in vitro. The data will bridge receptor pharmacology in standard cell lines
with in vivo data from Aim 3 and can validate and expand biomarkers for fibrosis. (3) Assess anti-fibrotic effects
of a CB2 agonist antibody in an in vivo model of liver fibrosis (with leading liver fibrosis expert and Consortium
PI, Dr. Scott Friedman). This aim will test the feasibility of using CB2 agonism to treat liver fibrosis in
thioacetamide rat models by measuring the effects of the antibody on blood markers, collagen levels,
histopathology metrics, and gene expression.
Success in the Phase I project will lead to a safe and effective drug for liver fibrosis, increase scientific
understanding of liver disease, and define non-invasive biomarkers to monitor disease progression. Phase II
(including IND-enabling studies) will involve selecting and optimizing a lead antibody, with a focus on good
clinical and manufacturing attributes. This research will enable Abalone Bio to expand the impact of its CB2
antibody agonist drugs to other diseases involving fibrosis and inflammation, e.g., skin and lung diseases such
as scleroderma and idiopathic pulmonary fibrosis.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT L. FRIEDMAN其他文献
SCOTT L. FRIEDMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT L. FRIEDMAN', 18)}}的其他基金
Training Program in Investigative Gastroenterology and Hepatology
胃肠病学和肝病学研究培训计划
- 批准号:
10628499 - 财政年份:2023
- 资助金额:
$ 34.9万 - 项目类别:
Hepatic stellate cells in NASH fibrosis and HCC
NASH 纤维化和 HCC 中的肝星状细胞
- 批准号:
10350710 - 财政年份:2021
- 资助金额:
$ 34.9万 - 项目类别:
Hepatic stellate cells in NASH fibrosis and HCC
NASH 纤维化和 HCC 中的肝星状细胞
- 批准号:
10182514 - 财政年份:2021
- 资助金额:
$ 34.9万 - 项目类别:
Hepatic stellate cells in NASH fibrosis and HCC
NASH 纤维化和 HCC 中的肝星状细胞
- 批准号:
10597033 - 财政年份:2021
- 资助金额:
$ 34.9万 - 项目类别:
Therapeutic antibodies for treating liver fibrosis
用于治疗肝纤维化的治疗性抗体
- 批准号:
10666671 - 财政年份:2020
- 资助金额:
$ 34.9万 - 项目类别:
Therapeutic antibodies for treating liver fibrosis
用于治疗肝纤维化的治疗性抗体
- 批准号:
10547688 - 财政年份:2020
- 资助金额:
$ 34.9万 - 项目类别:
Autophagy during hepatic stellate cell activation in alcoholic liver injury
酒精性肝损伤肝星状细胞激活过程中的自噬
- 批准号:
8334729 - 财政年份:2011
- 资助金额:
$ 34.9万 - 项目类别:
Autophagy during hepatic stellate cell activation in alcoholic liver injury
酒精性肝损伤肝星状细胞激活过程中的自噬
- 批准号:
8504895 - 财政年份:2011
- 资助金额:
$ 34.9万 - 项目类别:
Autophagy during hepatic stellate cell activation in alcoholic liver injury
酒精性肝损伤肝星状细胞激活过程中的自噬
- 批准号:
8705327 - 财政年份:2011
- 资助金额:
$ 34.9万 - 项目类别:
相似海外基金
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10412227 - 财政年份:2022
- 资助金额:
$ 34.9万 - 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10610473 - 财政年份:2022
- 资助金额:
$ 34.9万 - 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
- 批准号:
10799162 - 财政年份:2022
- 资助金额:
$ 34.9万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6639179 - 财政年份:2001
- 资助金额:
$ 34.9万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6724797 - 财政年份:2001
- 资助金额:
$ 34.9万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6636512 - 财政年份:2001
- 资助金额:
$ 34.9万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6326889 - 财政年份:2001
- 资助金额:
$ 34.9万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6266928 - 财政年份:2001
- 资助金额:
$ 34.9万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6539099 - 财政年份:2001
- 资助金额:
$ 34.9万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6520329 - 财政年份:2001
- 资助金额:
$ 34.9万 - 项目类别: